Skip to main content
Erschienen in: Reactions Weekly 1/2020

01.07.2020 | Case report

Nilotinib/ruxolitinib

Lack of efficacy, B-cell lymphoma and Hodgkin's lymphoma: 4 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Schwaab J, et al. Response to tyrosine kinase inhibitors in myeloid neoplasms associated with PCM1-JAK2, BCR-JAK2 and ETV6-ABL1 fusion genes. American Journal of Hematology 95: 824-833, No. 7, Jul 2020. Available from: URL: http://doi.org/10.1002/ajh.25825 Schwaab J, et al. Response to tyrosine kinase inhibitors in myeloid neoplasms associated with PCM1-JAK2, BCR-JAK2 and ETV6-ABL1 fusion genes. American Journal of Hematology 95: 824-833, No. 7, Jul 2020. Available from: URL: http://​doi.​org/​10.​1002/​ajh.​25825
Metadaten
Titel
Nilotinib/ruxolitinib
Lack of efficacy, B-cell lymphoma and Hodgkin's lymphoma: 4 case reports
Publikationsdatum
01.07.2020
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2020
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-020-81256-9

Weitere Artikel der Ausgabe 1/2020

Reactions Weekly 1/2020 Zur Ausgabe

Case report

Alemtuzumab

Case report

Ruxolitinib

Case report

Anaesthetics

Case report

Antineoplastics